Inhibition of arterial thrombus formation by apoA1 Milano

Dayuan Li, Sharon Weng, Baichun Yang, Dani S. Zander, Tom Saldeen, Wilmer W. Nichols, Saeed Khan, Jawahar L. Mehta

Research output: Contribution to journalArticlepeer-review


The mutant form of human apoA1, known as apoA1 Milano, is formed as a result of arginine 173 to cysteine substitution and inhibits experimental atherosclerosis in cholesterol-fed animals. This study was designed to determine if apoA1 Milano would modify arterial thrombogenesis. Sprague Dawley rats were intravenously administered the carrier alone (n=8) or apoA1 Milano (20 mg · kg-1 · d-1 for 4 to 10 days, n=17). The abdominal cavity was opened, and the abdominal aorta was isolated. Whatman paper impregnated with 35% FeCl3 was wrapped around the surface of the aorta, and aortic flow was recorded continuously. In carrier-treated rats, an occlusive platelet-fibrin-rich thrombus was formed in 21.2±4.1 (mean±SD) minutes. Treatment of rats with apoA1 Milano markedly delayed time to thrombus formation (38.8±11.9 versus 21.2±4.1 minutes, P

Original languageEnglish (US)
Pages (from-to)378-383
Number of pages6
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Issue number2
StatePublished - 1999
Externally publishedYes


  • ApoA1
  • Apolipoproteins
  • Lipoproteins, HDL
  • Thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Inhibition of arterial thrombus formation by apoA1 Milano'. Together they form a unique fingerprint.

Cite this